Durvalumab vs HLX43
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline
Durvalumab
Marketed by AstraZeneca and partners
NCT02125461 · Phase 3 · completed
Patients were randomly assigned in a 2:1 ratio and quadruple-blinded to durvalumab or matching placebo, with 476 receiving durvalumab and 237 placebo. The prespecified primary clinical endpoints were met: progression-free survival was 16.8 versus 5.6 months (HR 0.52, p<0.0001), and overall survival also favored durvalumab (HR 0.68, p=0.00251).
Next expected readout: December 2026 · NCT05000710 (registry estimate)
Reported efficacy
Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.); Overall Survival (From baseline until death due to any cause. Assessed until 22 Mar 2018 DCO; up to a maximum of approximately 4 years.): Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8) (met)
Result source: NCT02125461
HLX43
Developed by Shanghai Henlius Biotech
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: June 2027 · NCT07253142 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Durvalumab | HLX43 |
|---|---|---|
| PFS, median | 16.8 vs 5.6+11.2 vs placeboNCT0212546124 other results
| —Trial running · NCT07459751 |
| OS, median | 11.7 vs 8.7vs SoCNCT0235294820 other results
| —Trial running · NCT07459751 |
| ORR | 60.7% vs 60.6%+0.1 vs placeboNCT0351997110 other results
| —Trial running · NCT07459751 |
| Duration of response, median | 30.7 vs 18.6+12.1 vs placeboNCT0351997117 other results
| —Trial running · NCT07459751 |
PFS, median
- Durvalumab
- 16.8 vs 5.6+11.2 vs placeboNCT02125461
24 other results
- 13.8 vs 9.4 NCT03519971
- 16.7 vs 15.6 NCT04026412
- 3.8 vs 3.5 NCT02352948
- 3.5 vs 3.5 NCT02352948
- 6.2 vs 5.5 NCT03164616
- 16.8 vs 15.7 NCT04026412
- 17.4 vs 15.7 NCT04026412
- 16.8 vs 16.5 NCT04026412
- 17.7 vs 16.5 NCT04026412
- 3.5 NCT02352948
- 3.1 NCT02352948
- 21.1 vs 7.3 NCT03822351
- 19.8 vs 7.3 NCT03822351
- 10.3 NCT04249362
- 7.6 NCT04249362
- 13.1 NCT03693300
- 3 NCT02879617
- 2 NCT03164772
- 1.8 NCT03164772
- 2 NCT03164772
- 1.8 NCT03164772
- 20.4 NCT03801902
- 30.2 NCT03801902
- 3.7 NCT03693300
- HLX43
- —Trial running · NCT07459751
OS, median
- Durvalumab
- 11.7 vs 8.7vs SoCNCT02352948
20 other results
- 11.5 vs 8.7 NCT02352948
- 36.4 vs 29.5 NCT03519971
- 14 vs 13.3 NCT03164616
- 34.6 vs 39.8 NCT04026412
- 39.5 vs 39.8 NCT04026412
- 11.5 NCT02352948
- 10 NCT02352948
- 6 NCT02879617
- 13.3 NCT02087423
- 10.9 NCT02087423
- 9.3 NCT02087423
- 39 NCT03693300
- 9.9 NCT02087423
- 13.2 NCT02087423
- 21.1 NCT04249362
- 16.8 NCT04249362
- 7.5 NCT03164772
- 16.0 NCT04003246
- 23.5 NCT03164772
- 12.3 NCT03693300
- HLX43
- —Trial running · NCT07459751
ORR
- Durvalumab
- 60.7% vs 60.6%+0.1 vs placeboNCT03519971
10 other results
- 35.5% vs 6.8% NCT02352948
- 14.9% vs 6.8% NCT02352948
- 15.4% vs 6.8% NCT02352948
- 67.6% vs 64.5% NCT04026412
- 72.2% vs 64.5% NCT04026412
- 61.3% vs 57.9% NCT04026412
- 63.1% vs 57.9% NCT04026412
- 35% vs 23.9% NCT03822351
- 40.3% vs 23.9% NCT03822351
- 58.1% NCT02572843
- HLX43
- —Trial running · NCT07459751
Duration of response, median
- Durvalumab
- 30.7 vs 18.6+12.1 vs placeboNCT03519971
17 other results
- 9.5 vs 10.8 NCT02352948
- 12.2 vs 10.8 NCT02352948
- 10 vs 10.8 NCT02352948
- 7.4 vs 6 NCT03164616
- 25.8 vs 25.2 NCT04026412
- 31.8 vs 25.2 NCT04026412
- 22.8 vs 27.9 NCT04026412
- 33.2 vs 27.9 NCT04026412
- 29.9 NCT03822351
- 23 NCT03822351
- 12.3 NCT02087423
- 13.1 NCT04249362
- 7.9 NCT04249362
- 9.9 NCT03164772
- 5.8 NCT03164772
- 9.9 NCT03164772
- 5.8 NCT03164772
- HLX43
- —Trial running · NCT07459751
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HLX43: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Durvalumab: 4 of 4 rows · HLX43: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Durvalumab |
|---|---|
| Dropout rate | 62.6%a NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results79%Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 75.2%Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 74.1%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 n/a: no completion milestone NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 76.3% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 31% NCT04416633 · Phase 4 · registry result, not featured evidence 64.1%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 100% NCT04642469 · Phase 3 · registry result, not featured evidence 26.7% NCT04385368 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence —Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence 0%Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence 0%Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence 90% NCT04003246 · Phase 2 · registry result, not featured evidence 1.5% NCT02572843 · Phase 2 · registry result, not featured evidence 51.7%Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination 51.6%Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence 66.7%Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence 13.3%Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy 13.3%Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination 0% NCT02879617 · Phase 2 · registry result, not featured evidence 3.7%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 6.3%1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 14.3%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 78.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 91.2%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 7.1%Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence 0%Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results—Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 — NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 6% NCT04416633 · Phase 4 · registry result, not featured evidence —Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination —Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination — NCT04642469 · Phase 3 · registry result, not featured evidence — NCT04385368 · Phase 3 · registry result, not featured evidence · combination —Cohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence —Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence —Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence —Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence — NCT04003246 · Phase 2 · registry result, not featured evidence — NCT02572843 · Phase 2 · registry result, not featured evidence —Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence —Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence —Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy —Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination — NCT02879617 · Phase 2 · registry result, not featured evidence —1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence —1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination —1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination —1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 4.3%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 11.8%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination —Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence —Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 29.1%a NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 34 more results37.1%Sub-study A: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 30.8%Sub-study B: Durvalumab NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 37.6%Sub-study B: Durvalumab+Tremelimum NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 47% NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 44.2% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 21% NCT04416633 · Phase 4 · registry result, not featured evidence 63.8%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 7.1% NCT04642469 · Phase 3 · registry result, not featured evidence 31.1% NCT04385368 · Phase 3 · registry result, not featured evidence · combination 16.2%Cohort 1 (EGFR/ALK+) NCT02087423 · Phase 2 · registry result, not featured evidence · combination 29.1%Cohort 2 NCT02087423 · Phase 2 · registry result, not featured evidence 35.3%Cohort 3 (TC >=90%) NCT02087423 · Phase 2 · registry result, not featured evidence 43.4%Durvalumab Cohort A: Standard Radi NCT04249362 · Phase 2 · registry result, not featured evidence 36.7%Durvaumab Cohort B: Palliative Rad NCT04249362 · Phase 2 · registry result, not featured evidence 70% NCT04003246 · Phase 2 · registry result, not featured evidence 53.7% NCT02572843 · Phase 2 · registry result, not featured evidence —Arm A (Durvalumab + Oleclumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination —Arm B (Durvalumab + Monalizumab) NCT03822351 · Phase 2 · registry result, not featured evidence · combination 27.9%Durvalumab + Monalizumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination 33.9%Durvalumab + Oleclumab NCT03822351 · Phase 2 · registry result, not featured evidence · combination 28.1%Durvalumab ECOG PS 0 or 1 NCT03693300 · Phase 2 · registry result, not featured evidence 0%Durvalumab ECOG PS 2 NCT03693300 · Phase 2 · registry result, not featured evidence 40%Arm 1 (Durvalumab Monotherapy) NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy 50%Arm 2 (Durvalumab Plus SBRT) NCT02904954 · Phase 2 · registry result, not featured evidence · combination 55.3% NCT02879617 · Phase 2 · registry result, not featured evidence 11.5%1500 mg NCT03794544 · Phase 2 · registry result, not featured evidence 31.3%1500 mg + 200 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 5%1500 mg + 750 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 9.5%1500 mg + 3000 mg NCT03794544 · Phase 2 · registry result, not featured evidence · combination 60.9%Arm A: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 64.7%Arm B: BI 1361849 mRNA Vaccine + D NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination 46.2%Arm I (CLOSED) (Durvalumab and ACR NCT03801902 · Phase 1 · registry result, not featured evidence 41.7%Arm II (CLOSED) (Durvalumab and St NCT03801902 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a cough 35.6% (placebo 25.2%) fatigue 24% (placebo 20.1%) dyspnoea 22.3% (placebo 24.4%) NCT02125461 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 32 more resultsdecreased appetite 25.8% constipation 21% cough 17.7% NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 decreased appetite 23.1% diarrhoea 21.4% fatigue 18.8% NCT02352948 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 diarrhoea 20.8% decreased appetite 19.7% asthenia 17.9% NCT02352948 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 41.1% (placebo 37%) neutropenia 26.9% (placebo 25.9%) nausea 25.1% (placebo 24.1%) NCT03519971 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 45.5% nausea 41.2% neutropenia 29.7% NCT03164616 · Phase 3 · combination · Non-Small Cell Lung Cancer · phase 3 anaemia 44% nausea 34.8% constipation 29.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination anaemia 41.5% nausea 32.7% cough 26.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination hypothyroidism 28.6% (placebo 0%) asthenia 21.4% (placebo 0%) pruritus 21.4% (placebo 0%) NCT04642469 · Phase 3 · registry result, not featured evidence nausea 42.2% (placebo 40.9%) anaemia 33.3% (placebo 27.3%) fatigue 33.3% (placebo 27.3%) NCT04385368 · Phase 3 · registry result, not featured evidence · combination cough 23.4% decreased appetite 13.5% fatigue 13.5% NCT02087423 · Phase 2 · registry result, not featured evidence · combination decreased appetite 26.8% fatigue 26% cough 21.1% NCT02087423 · Phase 2 · registry result, not featured evidence fatigue 29.4% constipation 23.5% cough 19.1% NCT02087423 · Phase 2 · registry result, not featured evidence anaemia 24.5% asthenia 24.5% dyspnoea 20.8% NCT04249362 · Phase 2 · registry result, not featured evidence cough 24.5% constipation 20.4% fatigue 20.4% NCT04249362 · Phase 2 · registry result, not featured evidence weight loss 80% anorexia 70% fatigue 70% NCT04003246 · Phase 2 · registry result, not featured evidence fatigue 68.7% nausea 67.2% diarrhea 62.7% NCT02572843 · Phase 2 · registry result, not featured evidence cough 42.6% asthenia 24.6% pruritus 24.6% NCT03822351 · Phase 2 · registry result, not featured evidence · combination cough 32.2% dyspnoea 25.4% asthenia 18.6% NCT03822351 · Phase 2 · registry result, not featured evidence · combination cough 37.7% asthenia 25.4% dyspnoea 23.7% NCT03693300 · Phase 2 · registry result, not featured evidence asthenia 66.7% cough 66.7% dyspnoea 66.7% NCT03693300 · Phase 2 · registry result, not featured evidence constipation 66.7% fatigue 60% cough 43.3% NCT02904954 · Phase 2 · registry result, not featured evidence · monotherapy constipation 70% anemia 53.3% fatigue 46.7% NCT02904954 · Phase 2 · registry result, not featured evidence · combination anemia 63.8% hypoalbuminemia 55.3% lymphocyte count decreased 48.9% NCT02879617 · Phase 2 · registry result, not featured evidence 1500 mg fatigue 23.1% procedural pain 19.2% asthenia 11.5% NCT03794544 · Phase 2 · registry result, not featured evidence 1500 mg + 200 mg dyspnoea 18.8% fatigue 18.8% alanine aminotransferase increased 12.5% NCT03794544 · Phase 2 · registry result, not featured evidence · combination 1500 mg + 750 mg constipation 10% fatigue 10% pruritus 10% NCT03794544 · Phase 2 · registry result, not featured evidence · combination 1500 mg + 3000 mg fatigue 19% asthenia 14.3% cough 14.3% NCT03794544 · Phase 2 · registry result, not featured evidence · combination decreased appetite 34.8% fatigue 34.8% anaemia 30.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination cough 35.3% fatigue 32.4% nausea 32.4% NCT03164772 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 29 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Durvalumab
show 11 more results
show 10 more results
show 1 more result
show 11 more results
show 3 more results
show 4 more results
show 14 more results
show 3 more results
show 12 more results
+ 49 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Durvalumab's landscape · HLX43's landscape